Evidence map›Paper›PMID 33210210›Full record

ArticleJournal of cancer research and clinical oncology2021

PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma: a retrospective analysis from the University of Southern California.

Gino K In, Poorva Vaidya, Alexandra Filkins, David J Hermel, Kevin G King, Omar Ragab, William W Tseng, Mark Swanson, Niels Kokot, Julie E Lang and 10 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Immune checkpoint inhibitors in advanced cutaneous squamous cell carcinoma: A systemic review and meta-analysis.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2023
    Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. The Tumor Microenvironment in SCC: Mechanisms and Therapeutic Opportunities.Frontiers in cell and developmental biology · 2021
    Review
  17. Article
  18. Article
  19. Personalized treatment concepts in extraocular cancer.Advances in ophthalmology practice and research
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 1 country.

Gino K InUSC Norris Comprehensive Cancer Center, 1441 Eastlake Ave, NTT 3449, Los Angeles, CA, 90033, USA. gino.in@med.usc.edu.ORCID http://orcid.org/0000-0002-7060-5123
Poorva VaidyaDepartment of Medicine, USC Keck School of Medicine, Los Angeles, CA, USA.
Alexandra FilkinsDepartment of Medicine, USC Keck School of Medicine, Los Angeles, CA, USA.
David J HermelDivision of Hematology/Oncology, Scripps Clinic, La Jolla, CA, USA.
Kevin G KingDepartment of Radiology, USC Keck School of Medicine, Los Angeles, CA, USA.
Omar RagabDepartment of Radiation Oncology, USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
William W TsengDepartment of Surgery, Division of Breast, Endocrine and Soft Tissue Surgery, USC Keck School of Medicine, Los Angeles, CA, USA.
Mark SwansonCaruso Department of Otolaryngology-Head and Neck Surgery, USC Keck School of Medicine, Los Angeles, CA, USA.
Niels KokotCaruso Department of Otolaryngology-Head and Neck Surgery, USC Keck School of Medicine, Los Angeles, CA, USA.
Julie E LangDepartment of Surgery, Division of Breast, Endocrine and Soft Tissue Surgery, USC Keck School of Medicine, Los Angeles, CA, USA.
Lawrence MenendezDepartment of Orthopaedic Surgery, USC Keck School of Medicine, Los Angeles, CA, USA.
Brittney DeClerckDepartment of Dermatology, USC Keck School of Medicine, Los Angeles, CA, USA.
Gene KimDepartment of Dermatology, USC Keck School of Medicine, Los Angeles, CA, USA.
Jenny C HuDepartment of Dermatology, USC Keck School of Medicine, Los Angeles, CA, USA.
Alicia TerandoDepartment of Surgery, Division of Breast, Endocrine and Soft Tissue Surgery, USC Keck School of Medicine, Los Angeles, CA, USA.
Hossein JadvarDepartment of Radiology, USC Keck School of Medicine, Los Angeles, CA, USA.
Charité RickerUSC Norris Comprehensive Cancer Center, 1441 Eastlake Ave, NTT 3449, Los Angeles, CA, 90033, USA.
Kimberly A MillerDepartment of Dermatology, USC Keck School of Medicine, Los Angeles, CA, USA.
David H PengDepartment of Dermatology, USC Keck School of Medicine, Los Angeles, CA, USA.
Ashley WysongDepartment of Dermatology, University of Nebraska Medical Center, Omaha, NE, USA.
Keck Hospital of USC · USUSC Norris Comprehensive Cancer Center · USScripps Clinic · USUniversity of Nebraska Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeApproximately 5% of patients with cutaneous squamous cell carcinoma (CSCC) may develop recurrent or metastatic disease. The management of such cases is challenging and requires multi-disciplinary care. Immunotherapy using PD-1 inhibition was approved to treat unresectable or metastatic CSCC in 2018. Given limited data regarding clinical outcomes outside of published trials, we describe our experience using this therapy.

methodsWe retrospectively reviewed all patients treated with PD-1 inhibition as therapy for locally advanced, regionally metastatic or distant metastatic CSCC at the University of Southern California. Clinicopathological characteristics, treatment data using PD-1 inhibitors, and outcomes were assessed.

resultsAmong 26 patients treated with PD-1 inhibition, the objective response rate was 42.3%, with 19.2% of patients having partial response and 23.1% having complete response to therapy. The median progression-free survival was 5.4 months. Median tumor mutational burden (TMB) was higher among responders compared to non-responders (60 vs. 9 Mut/Mb, p = 0.04). Primary CSCC tumor location on the head/neck was also associated with response to PD-1 inhibition (p = 0.04). Two patients with mutations affecting mismatch repair deficiency were noted to have complete response to treatment. No other variables were associated with treatment outcomes.

conclusionPD-1 inhibition produces durable responses among patients with advanced or metastatic CSCC. PD-1 inhibition therapy is well tolerated, but patients should be monitored closely for immune-related adverse events, particularly frail or immune-suppressed patients. Further investigation of potential biomarkers to help identify patients who will derive the most benefit from this therapeutic option is needed.

Indexed as

AdultAgedAged, 80 and overCaliforniaCarcinoma, Squamous CellDisease ProgressionFemaleHumansImmune Checkpoint InhibitorsMaleMiddle AgedNeoplasm MetastasisProgression-Free SurvivalRetrospective StudiesSkin NeoplasmsTreatment OutcomeImmune Checkpoint InhibitorsCheckpoint blockadeCutaneous squamous cell carcinomaImmunotherapyPD-1Skin cancer

Identifiers

PMID33210210
PMCPMC11801844
OpenAlexW3099991668

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.